ReviewYonsei medical journal2009
Update on recent advances in the management of aspirin exacerbated respiratory disease.
Review in Yonsei medical journal, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 49 citations in OpenAlex.
- [Expert consensus on the diagnosis and treatment of respiratory diseases exacerbated by nonsteroidal anti-inflammatory drugs （2024, Chengdu）].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2024Article
- Investigation of the Relationship between Aspirin-Sensitivity and Poor Response to Medical Management in NSAIDs-exacerbated Respiratory Disease Patients with Sinonasal Polyposis.Medical journal of the Islamic Republic of Iran · 2023Article
- NSAID-Exacerbated Respiratory Disease (NERD): From Pathogenesis to Improved Care.Frontiers in pharmacology · 2020Review
- Samter's Triad: State of the Art.Clinical and experimental otorhinolaryngology · 2018Review
- Genetic and Epigenetic Components of Aspirin-Exacerbated Respiratory Disease.Immunology and allergy clinics of North America · 2016Review
- Review
- Genome-Wide Association Study Identifies Novel Pharmacogenomic Loci For Therapeutic Response to Montelukast in Asthma.PloS one · 2015Article
- Clinical features of elderly chronic urticaria.The Korean journal of internal medicine · 2014Article
- Polymorphisms of ATF6B Are Potentially Associated With FEV1 Decline by Aspirin Provocation in Asthmatics.Allergy, asthma & immunology research · 2014Article
- Major comorbid conditions in asthma and association with asthma-related hospitalizations and emergency department admissions in adults: results from the German National Health Telephone Interview Survey (GEDA) 2010.BMC pulmonary medicine · 2013Article
- A genetic effect of IL-5 receptor α polymorphism in patients with aspirin-exacerbated respiratory disease.Experimental & molecular medicine · 2013Article
- [Aspirin desensitization: therapy options in patients with aspirin-exacerbated respiratory disease].HNO · 2012Article
- Genetic mechanisms in aspirin-exacerbated respiratory disease.Journal of allergy · 2012Article
- Aspirin sensitivity and chronic rhinosinusitis with polyps: a fatal combination.Journal of allergy · 2012Article
- Role of TSLP in Nasal Polyp Inflammation.Allergy, asthma & immunology research · 2011Article
- Therapeutic applications.Sub-cellular biochemistry · 2011Review
- The role of aspirin desensitization in patients with aspirin-exacerbated respiratory disease (AERD).Brazilian journal of otorhinolaryngologyArticle
- Symptom-Based Clustering in Chronic Rhinosinusitis Relates to History of Aspirin Sensitivity and Postsurgical Outcomes.The journal of allergy and clinical immunology. In practiceArticle
- Rhinosinusitis: evidence and experience: October 18 and 19, 2013 - São Paulo.Brazilian journal of otorhinolaryngologyArticle
- Epidemiology and differential diagnosis of nasal polyps.American journal of rhinology & allergyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aspirin intolerant asthma (AIA) is frequently characterized as an aspirin (ASA)-exacerbated respiratory disease (AERD). It is a clinical syndrome associated with chronic severe inflammation in the upper and lower airways resulting in chronic rhinitis, sinusitis, recurrent polyposis, and asthma. AERD generally develops secondary to abnormalities in inflammatory mediators and arachidonic acid biosynthesis expression. Upper and lower airway eosinophil infiltration is a key feature of AERD; however, the exact mechanisms of such chronic eosinophilic inflammation are not fully understood. Cysteinyl leukotriene over-production may be a key factor in the induction of eosinophilic activation. Genetic studies have suggested a role for variability of genes in disease susceptibility and response to medication. Potential genetic biomarkers contributing to the AERD phenotype include HLA-DPB1*301, LTC4S, ALOX5, CYSLT, PGE2, TBXA2R, TBX21, MS4A2, IL10 -1082A > G, ACE -262A > T, and CRTH2 -466T > C; the four-locus SNP set was composed of B2ADR 46A > G, CCR3 -520T > G, CysLTR1 -634C > T, and FCER1B -109T > C. Management of AERD is an important issue. Aspirin ingestion may result in significant morbidity and mortality, and patients must be advised regarding aspirin risk. Leukotriene receptor antagonists (LTRA) that inhibit leukotriene pathways have an established role in long-term AERD management and rhinosinusitis. Aspirin desensitization may be required for the relief of upper and lower airway symptoms in AERD patients. Future research should focus on identification of biomarkers for a comprehensive diagnostic approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.